BarnesT, BraudeW: Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry, 42:874–878, 1985.
2.
Espi ForcenF: Akathisia: Is restlessness a primary condition or an adverse drug effect?. Curr Psychiatry, 14:14–18, 2015.
3.
Espi ForcenF, MatsoukasK, AliciY: Antipsychotic induced akathisia in delirium: A systematic review. Palliat Support Care, 14:77–84, 2016.
4.
FindlingRL, CavusI, PappadopulosE, et al.: Ziprasidone in adolescents with schizophrenia: Results from a placebo-controlled efficacy and long-term open-extension study. J Child Adolesc Psychopharmacol, 23:531–544, 2013a.
5.
FindlingRL, McNamaraNK, BranickyLA, et al.: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry, 39:509–516, 2000.
6.
FindlingRL, PathakS, LiuS, DelBelloM: Safety, tolerability, and efficacy of quetiapine in youth with schizophrenia or bipolar I disorder: A 26-week, open-label, continuation study. J Child Adolesc Psychopharmacol, 23:490–501, 2013b.
7.
KaneJM, BarnesTR, CorrellCU, SachsG, BuckleyP, EudiconeJ, et al.: Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: A post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol, 24:1019–1029, 2010.
8.
KimJH, SonYD, KimHK, et al.: Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: A high-resolution PET study with [11C]raclopride. J Clin Psychopharmacol, 31:507–511, 2011.
